FSD Pharma (TSE:HUGE) has released an update.
FSD Pharma Inc., a biopharmaceutical firm, has struck a deal with IR Agency LLC to bolster investor relations and expand its digital community. This one-month agreement, costing C$335,699, aims to enhance the company’s financial community profile starting May 28, 2024. FSD Pharma continues to focus on developing innovative treatments for neurodegenerative and metabolic disorders, including their lead compound, Lucid-MS, for combating myelin degradation in multiple sclerosis.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
